Eucure Biopharma Subsidiary of Biocytogen Collaborated with ISU ABXIS to Develop Tri-Specific Antibodies Using YH003 Antibody Sequence
Shots:
- Eucure Biopharma to receive an up front & is also eligible to receive milestones along with royalties
- The collaboration enables ISU ABXIS to use the sequence of Biocytogen’s YH003 (humanized IgG2 agonistic CD40 Ab) to develop tri-specific Abs and cancer drugs for multiple indications by leveraging its technology platform
- Biocytogen used its unique evidence-based in vivo drug screening platform to obtain YH003. The P-I trial of YH003 showed good tolerability & safety profiles along with encouraging antitumor activities against multiple tumor types, incl. MM & pancreatic cancer. The therapy is currently being studied in the P-II MRCTs for unresectable/metastatic PDAC & melanoma in Australia, the US & China
Ref: Businesswire | Image: Eucure Biopharma
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
